Research into the benefits of polymorphs is proceeding at a revolutionary rate.

What does the future hold for these exciting prospects and the companies who are investing these innovations?

Join Simon Bates, our host for this episode and Business Development Manager at Rigaku Americas Corporation, as he engages in a lively roundtable discussion with six industry experts on the future of polymorphs and current challenges.

What we talked about:

- Stunning evolutionary advances in the field of pharmaceutical polymorphs.

- Bringing in computational and big data solutions.

- Challenges in patentability for smaller companies.

- A bright future in polymorphism.

Today’s amazing guests:

- Steve Byrn, Professor and Dept. Head at Purdue University

- Raj Suryanarayanan, Professor at University of Minnesota

- Ann Newman, Solid-State and Pharmaceutical Consultant at Seventh Street Development Group

- Ken Morris, University Professor, Director Lachman Institute for Pharmaceutical Analysis, Long Island University

- Eyal Barash, Life Sciences Patent Attorney

- Mansoor Khan, Professor and Vice Dean, Presidential Impact Fellow, Texas A&M University, Rangel College of Pharmacy

For more insights into the pharmaceutical industry, subscribe to the show on Apple Podcasts, Spotify, or wherever podcasts are found.

Listening on a desktop & can’t see the links? Just search for The Pharma Lab Show in your favorite podcast player.

The Role of Polymorphism in the Future of Pharma